Accelerated partial breast irradiation using multicatheter brachytherapy for select early-stage breast cancer: local control and toxicity by Yeo, Seung-Gu et al.
Yeo et al. Radiation Oncology 2010, 5:56
http://www.ro-journal.com/content/5/1/56
Open Access RESEARCH
© 2010 Yeo et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons At-
tribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any
medium, provided the original work is properly cited.
Research Accelerated partial breast irradiation using 
multicatheter brachytherapy for select early-stage 
breast cancer: local control and toxicity
Seung-Gu Yeo*1,2, Juree Kim2,6, Geum-Hee Kwak3, Ji-Young Kim4, Kyeongmee Park5, Eun Seok Kim1 and Sehwan Han3
Abstract
Background: To investigate the efficacy and safety of accelerated partial breast irradiation (APBI) via high-dose-rate 
(HDR) multicatheter interstitial brachytherapy for early-stage breast cancer.
Methods: Between 2002 and 2006, 48 prospectively selected patients with early-stage breast cancer received APBI 
using multicatheter brachytherapy following breast-conserving surgery. Their median age was 52 years (range 36-78). 
A median of 34 Gy (range 30-34) in 10 fractions given twice daily within 5 days was delivered to the tumor bed plus a 1-
2 cm margin. Most (92%) patients received adjuvant systemic treatments. The median follow-up was 53 months (range 
36-95). Actuarial local control rate was estimated from surgery using Kaplan-Meier method.
Results: Local recurrence occurred in two patients. Both were true recurrence/marginal miss and developed in 
patients with close (< 0.2 cm) surgical margin after 33 and 40 months. The 5-year actuarial local recurrence rate was 
4.6%. No regional or distant relapse and death has occurred to date. Late Grade 1 or 2 late skin and subcutaneous 
toxicity was seen in 11 (22.9%) and 26 (54.2%) patients, respectively. The volumes receiving 100% and 150% of the 
prescribed dose were significantly higher in the patients with late subcutaneous toxicity (p = 0.018 and 0.034, 
respectively). Cosmesis was excellent to good in 89.6%.
Conclusions: APBI using HDR multicatheter brachytherapy yielded local control, toxicity, and cosmesis comparable to 
those of conventional whole breast irradiation for select early-stage breast cancer. Patients with close resection 
margins may be ineligible for APBI.
Background
Over the last decades, breast-conserving surgery (BCS)
followed by whole breast irradiation (WBI) became the
standard of care for the treatment of early-stage breast
cancer. However, the 5-6 weeks of conventional WBI are
problematic for elderly patients, working women, and
those who live a great distance from a radiotherapy facil-
ity [1]. In addition, controversies and logistical problems
exist that are associated with integrating this prolonged
course of WBI and systemic chemotherapy [2]. These
make a barrier to the acceptance of breast conservation
by patients or their physicians, and some patients do not
receive WBI after BCS [3].
The rationale underlying the accelerated partial breast
irradiation (APBI) is that in-breast failure for select low-
risk patients occurs mostly in the immediate area of the
tumor bed [4]. The risk of failing at a location remote
from the tumor bed is very low; it occurs despite WBI
and its rate is similar to that of new contralateral breast
cancer [5,6]. Accordingly, standard elective irradiation of
the entire breast for presumed occult disease can be
replaced with partial breast irradiation. The reduction in
irradiation volume allows the administration of a larger
fraction dose in a shorter period without significant addi-
tional toxicity. In addition, WBI-induced cardiovascular
mortality, which counteracted an increase in overall sur-
vival by adding WBI after BCS, may be reduced using
APBI by avoiding radiation exposure to coronary vessels
[7].
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Several centers have evaluated the feasibility and effi-
cacy of APBI and produced evidences supporting the use
of APBI for select early-stage breast cancer patients [8-
10]. W e pioneered APBI in our country, and this is the
first report of long-term outcomes. The study investi-
gated the efficacy and safety of APBI using high-dose-rate
(HDR) multicatheter interstitial brachytherapy for select
early-stage breast cancer patients and the endpoints were
the local control rate, treatment toxicity, and cosmesis.
Methods
Patients
This study included 48 prospectively selected women
with breast cancer in whom adjuvant radiotherapy was
performed using interstitial brachytherapy alone after
BCS. They were treated between May 2002 and Decem-
ber 2006, at the Inje University Sanggye Paik Hospital.
We recommended interstitial brachytherapy for patients
who met all of the following criteria: (1) age > 35 years,
(2) tumor size ≤ 4 cm, (3) negative surgical margin, (4)
negative axillary lymph nodes or singular positive node
without extracapsular extension, (5) suitable breast anat-
omy for implantation, and (6) full recognition of possible
increased risk of local failure. Patients with invasive lobu-
lar histology, extensive intraductal carcinoma, or multifo-
c a l i t y  w e r e  e x c l u d e d .  T h e  s t u d y  w a s  a p p r o v e d  b y  o u r
institutional review board and written informed consent
was obtained from the patients.
The median patient age was 52 years (range 36-78).
Histological subtypes were invasive ductal carcinoma in
36 (75.0%) patients, medullary carcinoma in 6 (12.5%),
ductal carcinoma in situ in 5 (10.4%), and tubular carci-
noma in 1 (2.1%). The pathological T classification was
Tis in 5 (10.4%), T1 in 28 (58.3%), and T2 in 15 (31.3%).
The pathological N classification was N0 in 44 (91.7%)
and N1 in 4 (8.3%); one positive node without extracapsu-
lar extension was found out of 6-16 nodes retrieved. The
pathological resection margin was clear (≥ 0.2 cm) in 42
(87.5%) and close (> 0, < 0.2 cm) in 6 (12.5%) patients.
Further information on the patient, tumor, and treatment
characteristics is given in Table 1.
Treatments
All patients underwent BCS with gross total resection of
the primary tumor and a sentinel node biopsy (n = 29,
60.4%) or level I/II axillary dissection (n = 19, 39.6%).
Four titanium clips were positioned at the excision cavity
boundaries: superiorly, inferiorly, medially and laterally.
Four to six (median 5) guide needles were inserted during
surgery. A single (n = 17, 35.4%) or double (n = 31, 64.6%)
plane implant was performed. The needles were sepa-
rated from each other by 1-1.5 cm. The distance from the
implant plane to the thoracic wall or overlying skin
should not be < 1 cm. The needles were replaced with
flexible catheters and fixed with buttons.
Radiotherapy was started after receiving complete his-
tological reports, at an interval of 6-9 days after surgery.
The radiotherapy was planned using the PLATO
brachytherapy planning system (Nucletron BV,
Veenendaal, The Netherlands). Two post-implant isocen-
tric radiographs were taken on a simulator with variable
Table 1: Patient, tumor, and treatment characteristics
No (%)
Age
Range 36-78
Median 52
Tumor size (cm)
Range 0.4 - 4.0
Median 1.5
T classification
Tis 5 (10.4)
T1 28 (58.3)
T2 15 (31.3)
N classification
N0 44 (91.7)
N1 4 (8.3)
Histological subtype
Invasive ductal 36 (75.0)
Invasive medullary 6 (12.5)
Ductal carcinoma in situ 5 (10.4)
Invasive tubular 1 (2.1)
Hormone receptor
ER + and PR + 34 (70.8)
ER + and PR - 3 (6.3)
ER - and PR - 11 (22.9)
Resection margin
Clear (≥ 0.2 cm) 42 (87.5)
Close (> 0, < 0.2 cm) 6 (12.5)
Radiation therapy
34 Gy (3.4 Gy/fraction) 40 (83.3)
30 Gy (3.0 Gy/fraction) 8 (16.7)
Systemic therapy
Chemotherapy + Hormonal 
therapy
24 (50.0)
Hormonal therapy 15 (31.3)
Chemotherapy 5 (10.4)
None 4 (8.3)
Abbreviation: ER = estrogen receptor; PR = progesterone receptor.Yeo et al. Radiation Oncology 2010, 5:56
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angles and used for digitizing and three-dimensional
reconstruction of the catheters and clips. The dose points
were related to the active source positions, and they were
placed at a given distance (0.5-1 cm) from the catheters.
The distance and active source positions were defined
individually for each catheter, considering the location of
the clips. The size of the planning target volume was esti-
mated in such a way that the reference dose points were
1-2 cm from the clips in each direction. Then, the dose
points and geometry were optimized [11]. The median
prescribed reference dose was 34 Gy (n = 40) in 10 frac-
tions bid separated by a minimum 6-h interval within 5
days. Eight patients received 30 Gy in 10 fractions bid.
Patients were treated in the supine position using the
microSelectron HDR remote afterloading equipment
with iridium-192 (Nucletron BV). Before each radiother-
apy session, a radiation oncologist monitored the patients
for complications and checked the catheter placement. If
not all of the pathological criteria for sole interstitial
brachytherapy were met, then the interstitial brachyther-
apy was converted to boost irradiation followed by a
course of WBI and these patients were excluded from this
study.
To estimate the skin dose, a flexible wire cross was posi-
tioned on the skin surface as representatively as possible
above the active source positions. During the process of
digitizing the implants, the dose points were also assessed
with the help of two isocentric radiographs. Representa-
tive skin point doses were calculated and the maximum
skin dose was documented for each patient.
Chemotherapy was given to 29 (60.4%) patients starting
within 9 days of the start of brachytherapy: cyclophosph-
amide, methotrexate, and 5-fluorouracil in 26 and doxo-
rubicin, cyclophosphamide, and docetaxel in 3. Thirty-
nine (81.3%) patients received hormonal therapy: tamox-
ifen in 22 and an aromatase inhibitor in 17.
The patients were seen every 3 months for the first 2
years and every 6 months thereafter, with a physical
examination, chest X-ray, and blood tests. Mammogra-
phy and ultrasound examinations of the breast and abdo-
men were performed at 6 months after APBI and then
yearly thereafter.
Analysis
To quantify the dose distributions, volume parameters
and the dose homogeneity index (DHI) were calculated
using dose-volume histograms. The volume parameters
included the volumes receiving 100% and 150% of the
prescribed dose (V100 and V150, respectively). The DHI
was calculated as (V100 - V150)/V100, and was used to
assess the dosimetric quality.
Local recurrence was defined as the recurrence of can-
cer in the treated breast proven histologically. A true
recurrence/marginal miss was defined as a recurrence
within or immediately adjacent to the primary tumor site.
An elsewhere recurrence was defined as a local recur-
rence detected at least 2 cm from the surgical clips [12].
The actuarial rate of local recurrence was estimated from
the date of surgery using the Kaplan-Meier method.
The cosmetic evaluation was based on the standards set
forth in the Harvard criteria, which consisted of a four-
tiered grading system: excellent, good, fair, and poor [13].
Late toxicity of the skin and subcutaneous tissue was
scored according to the Radiation Therapy Oncology
Group (RTOG)/European Organization for Research and
Treatment of Cancer late radiation morbidity scoring
scheme [14]. The cosmesis and toxicity scores recorded at
the last follow-up were analyzed. To analyze the associa-
tion between the dosimetric parameters or chemotherapy
use and treatment toxicity, t-test, Fisher's exact test, or
the chi-square test was used, as appropriate. A p-value of
< 0.05 was deemed statistically significant. All statistical
tests were performed using SPSS software (release 14.0;
SPSS Inc., Chicago, IL, USA).
Results
Local control
The median follow-up period was 53 months (range 36-
95) and there was no death. Local recurrence occurred in
two patients 33 and 40 months after surgery. Both were
true recurrence/marginal miss and developed in patients
with close surgical margin (Table 2). The 5-year actuarial
local recurrence rate was 4.6%. No regional nodal or dis-
tant metastasis was detected. The patients with recur-
rences received salvage surgery and all patients were alive
without evidence of disease at the last follow-up.
Dosimetry, toxicity, and cosmesis
The mean V100 and V150 values were 44.7 ± 17.9 cm3
(range 12-101) and 22.8 ± 8.3 cm3 (range 5-46), respec-
tively. The mean DHI was 0.5 ± 0.03 (range 0.44-0.57).
The maximum skin dose ranged from 12-69% (median
39%) of the prescribed dose.
Early side effects were usually mild and the breast pain,
edema, or erythema subsided with conservative manage-
ment. Grade 1 and 2 late skin toxicity occurred in 8
(16.7%) and 3 (6.3%) patients, respectively. Grade 1 and 2
late subcutaneous toxicity developed in 19 (39.6%) and 7
(14.6%) patients, respectively. Asymptomatic fat necrosis
was detected on routine follow-up mammography in 5
(10.4%) patients, but required no surgical intervention.
Dosimetric parameters like the V100, V150, and DHI did
not differ significantly according to the occurrence of late
skin toxicity. V100 and V150 were significantly higher in the
patients with late subcutaneous toxicity (p = 0.018 and
0.034, respectively) (Table 3). The maximum skin doseY
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Table 2: Characteristic of the patients with local recurrence
No Age Pathology Tumor 
size (cm)
pN ER PR RM Radiation 
therapy
Systemic 
therapy
Failure Time to 
failure (mo)
Salvage 
surgery
Follow-up 
after salvage 
surgery (mo)
15 2 D C I S 1 . 8 0+- C l o s e 3 4  G y T A M T R / M M 3 3 B C S 2 1
24 2 I D C 2 . 2 0++ C l o s e 3 4  G y C M F /
TAM
TR/MM 40 MRM 13
Abbreviation: pN = pathological nodal classification; ER = estrogen receptor; PR = progesterone receptor; RM = resection margin; DCIS = ductal carcinoma in situ; IDC = invasive ductal carcinoma; 
TAM = tamoxifen; CMF = cyclophosphamide, methotrexate, 5-fluorouracil; TR/MM = true recurrence/marginal miss; BCS = breast-conserving surgery; MRM = modified radical mastectomy.Yeo et al. Radiation Oncology 2010, 5:56
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was 43 ± 12% and 37 ± 11% in the patients with and with-
out late skin toxicity, respectively (p = 0.190). The rates of
late treatment toxicities did not differ according to the
use of chemotherapy. Cosmesis was excellent (n = 34) or
good (n = 9) in 89.6% of the patients. No one had poor
cosmesis.
Discussion
Long-term results of the phase II multicenter APBI trials
for select early-stage breast cancer were recently reported
[8-10,15]. In the RTOG phase II trial [9], 66 patients
received HDR brachytherapy (34 Gy in 3.4 Gy bid for 5
days) and 33 patients received low-dose-rate brachyther-
apy (45 Gy). The estimated 5-year local recurrence rate
was 4% (3% in HDR and 6% in low-dose-rate) after a
median follow-up of 7 years. In the German-Austrian
phase II trial [10], 175 patients received pulsed-dose-rate
brachytherapy (49.8 Gy) and 99 received HDR
brachytherapy (32 Gy in 4 Gy bid for 4 days). After a
median follow-up of 32 months, the 3-year local recur-
rence rate was 0.4%. In the single-institution phase II trial
conducted in Hungary [8], 45 patients received HDR
brachytherapy, either 36.4 Gy (n = 37) or 30.3 Gy (n = 8)
in seven fractions for 4 days. After a median follow-up of
81 months, the 5-year local recurrence rate was 4.4%,
which was not significantly different from that for WBI in
a retrospective comparative analysis. Overall, recently
published APBI studies using multicatheter interstitial
brachytherapy reported annual local recurrence rates
below 1%, which is equivalent to the outcomes of WBI
[8,16]. We found a 4.6% 5-year local recurrence rate,
which translates to an annual recurrence rate of 0.9%, and
is not different from those of other institutions.
Patients who have a substantial chance of harboring
residual disease located a significant distance from the
edge of the excision cavity or who potentially have multi-
centric disease have been precluded from APBI trials.
The eligibility criteria of the RTOG trial included unicen-
tricity, T1 or T2 (≤ 3 cm), infiltrating nonlobular carci-
noma, pathologically negative margin, N0 or N1 without
extracapsular extension, and no extensive intraductal
component [9]. The eligibility criteria of the German-
Austrian trial included tumor diameter ≤ 3 cm, clear
resection margin (≥ 0.2 cm), N0 or singular nodal micro-
metastasis, estrogen and/or progesterone receptor posi-
tive, and ≥ 35 years [10]; patients were excluded if
multifocality, poor differentiation, an extensive intraduc-
tal component, or lymphovascular invasion existed.
Regarding resection margin, the American Brachyther-
apy Society recommended a negative margin, whereas
the American Society of Breast Surgeons recommended a
margin of at least 0.2 cm [4]. We experienced two local
recurrences which were true recurrence/marginal miss
and occurred to the patients with close resection margin.
P ositive margin status is generally accepted as a major
risk factor for local recurrence after BCS and radiother-
apy, and the width of clear surgical margins significantly
influences local tumor control [17]. At least 0.2 cm
tumor-free margins are deemed acceptable in some APBI
trials [10,18], but others also successfully treated patients
with close margins by APBI [8,9]. However, recently pub-
lished recommendations for APBI selection criteria cate-
gorized patients with close margins as an intermediate-
risk group, as there are only limited data supporting the
use of APBI for these patients [19]. Our results may indi-
cate that close margins should be an exclusion criterion
for APBI trials.
Table 3: Comparison of dosimetric parameters according to the late treatment toxicity
Toxicity No (%) V100 (cm3) P‡ V150 (cm3) P‡ DHI P‡
Skin
Yes* 11 (22.9) 51.3 ± 12.1 0.221 25.7 ± 6.2 0.222 0.51 ± 0.03 0.105
No 37 (77.1) 43.0 ± 18.9 22.0 ± 8.7 0.49 ± 0.03
Subcutaneous tissue
Yes† 26 (54.2) 50.2 ± 18.2 0.018 25.1 ± 8.1 0.034 0.50 ± 0.03 0.099
No 22 (45.8) 37.5 ± 15.0 19.9 ± 7.8 0.48 ± 0.03
Fat necrosis
Yes 5 (10.4) 40.4 ± 18.7 0.529 21.0 ± 9.8 0.560 0.48 ± 0.02 0.465
No 43 (89.6) 45.4 ± 17.9 23.1 ± 8.1 0.49 ± 0.03
Abbreviation: V100 and V150= volumes receiving 100% and 150% of the prescribed dose; DHI = dose homogeneity index, (V100 - V150)/V100.
*Grade 1 to 2 toxicity.
†Grade 1 to 2 toxicity. Five patients with asymptomatic fat necrosis also had grade 2 subcutaneous toxicity.
‡t-test.Yeo et al. Radiation Oncology 2010, 5:56
http://www.ro-journal.com/content/5/1/56
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The most commonly prescribed dose of sole HDR
brachytherapy for breast cancer is 34 Gy in ten fractions
bid, which is equivalent to a 46 Gy tumor dose using the
standard WBI scheme (2 Gy per day, 5 days per week)
[20]. Whether the higher local recurrence risk after
incomplete tumor excision can be counterbalanced by an
additional boost radiotherapy following WBI has not
been demonstrated clearly [21]; however, a HDR
brachytherapy boost of 13.2 Gy in three fractions follow-
ing 50 Gy/25 fractions WBI produced favorable local
control for close to positive margins [22]. The traditional
two X-ray film localization technique used in both this
study and other recent reports [8-10] cannot define the
actual extent of the target volume and it relates the pre-
scribed dose to the geometry of the implant and not to
the target volume. To localize the irregular three-dimen-
sional shape of the target volume and the normal tissue
structures correctly and to adapt the reference isodose
surface to the shape of this target volume, the utility of
brachytherapy planning based on computed tomography
imaging has been investigated [23,24]. With sophisticated
computed tomography-based implantation and three-
dimensional planning system, the target volume defini-
tion considering inadequate resection margin foci and
t h e  m o d u l a t i o n  o f  a  h i g h e r  d o s e  t o  c o v e r  t h i s  r e g i o n
might be efficient for those patients who have an insuffi-
cient resection margin.
Compared to the postoperative implantation [8-10],
intraoperative implantation has the advantages of direct
visualization of the excision cavity and shorter local treat-
ment period including surgery and radiotherapy [15].
One disadvantage is the inability to select patients prop-
erly for implantation based on definitive pathological
findings; however, brachytherapy was used as boost
radiotherapy before WBI when the pathology indicated
that the patient was unsuitable for brachytherapy alone.
Preliminary guidelines designed to reduce the toxicity
of HDR interstitial brachytherapy have been reported
[25]. First, ideally, less than 60% of the normal whole
breast volume should receive ≥ 50% of the prescribed
dose. In this respect, Asian women are at a disadvantage
due to their relatively small breasts compared to Euro-
pean and American women, and this might be one of the
reasons why APBI has not been actively investigated for
them [26]. To satisfy this recommendation, the imple-
mentation of computed tomography-based three-dimen-
sional planning would be advantageous. Second, one
must minimize hot spots (V150) and maintain DHI > 0.75.
We found that a higher V100 or V150 was associated with a
significantly higher rate of late subcutaneous toxicity.
Mean DHI was low as 0.5, however dose inhomogeneity
can make a positive contribution in terms of the tumor
control probability [27]. Third, the dose delivered to the
skin and chest wall should be less than the prescribed
dose. We selected patients with sufficient breast tissue
anterior to the tumor and the maximum skin dose was
restricted to below 70% of the prescribed dose. Finally,
one must proceed with caution if chemotherapy is to be
given following APBI. Adriamycin-based chemotherapy
after APBI was reportedly related to worse toxicity and
cosmesis [25]. We started chemotherapy (mostly not
adriamycin-based) during or right after APBI and the
chemotherapy use did not affect late toxicity. Previously,
we reported the non-inferior safety of concurrent chemo-
radiotherapy compared to sequential chemoradiotherapy
using WBI for early-stage breast cancer [2]. However, the
use of larger fraction dose in APBI compared to WBI may
necessitate careful administration of chemotherapy. Fur-
thermore, normal tissue changes after APBI have been
documented to evolve over time; some endpoint mea-
sures (cosmesis, edema, erythema, and breast pain)
improved with time, while others (fat necrosis, subcuta-
neous fibrosis, and telangiectasia) worsened [28,29].
These findings underscore the extended period needed to
monitor APBI-related late treatment toxicity, and some
patients in this study may need more follow-up to fully
evaluate late toxicity.
A few details of the methods need to be mentioned.
First, the relatively small breasts in the patients caused
concern for treatment toxicity owing to the high irradi-
ated volume/ipsilateral breast volume ratio. Thus, a
schedule of 30 Gy in 10 fractions was tried for the first
eight patients. After the feasibility and safety of APBI was
verified for these eight patients, a dose of 34 Gy in 10
fractions was adopted for the remaining patients. Second,
the number of catheters used was small (median 5), with
a single plane implant in 17 (35.4%) patients. We tried to
remove a tumor and at least 1 cm margin, while at the
same time trying to minimize the total excision volume
for cosmesis. APBI started shortly (6-9 days) after sur-
gery, and the hemovac drainage was maintained until
APBI completed. Accordingly, the excision cavity was less
likely to accumulate a hematoma or seroma, and the
mean V100 was relatively small, at 44.7 cm3. A single plane
implant was used when the excision cavity was small and
flat. However, an increase in catheter number, less use of
a single plane implant or computed tomography-based
three-dimensional dose planning would be necessary to
enhance dose homogeneity.
Conclusions
In conclusion, APBI using HDR multicatheter interstitial
brachytherapy for early-stage breast cancer yielded local
control, toxicity, and cosmesis comparable to those of
other recent APBI trials or conventional WBI. Our results
support the suggestion that APBI is a viable option for
select patients with breast cancer. Patients with close
resection margins may be ineligible for APBI, and studiesYeo et al. Radiation Oncology 2010, 5:56
http://www.ro-journal.com/content/5/1/56
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of novel brachytherapy techniques should be pursued to
optimize APBI outcomes.
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